modelCediranib
Extends from Pharmacolibrary.Drugs.ATC.L.L01EK02.
Information
| name: | Cediranib | |
| ATC code: | L01EK02 | route: | oral |
| compartments: | 1 | |
| dosage: | 45 | mg |
| volume of distribution: | 68 | L |
| clearance: | 32 | L/h |
| other parameters in model implementation | ||
Cediranib is an orally available small-molecule tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor (VEGF) receptors. It was developed primarily for its anti-angiogenic properties, targeting tumor blood vessel growth in various cancers. Cediranib has been investigated in clinical trials for malignancies such as ovarian, lung, and colorectal cancers, but as of 2024, it is not approved for routine clinical use by major regulatory agencies.
Pharmacokinetics
Pharmacokinetic parameters in adult cancer patients (various solid tumors) after single and multiple oral doses of cediranib.
References
Al-Huniti, N, et al., & Li, J (2018). Population exposure-safety analysis of cediranib for Phase I and II studies in patients with cancer. British journal of clinical pharmacology 84(4) 726–737. DOI:10.1111/bcp.13495 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29274100
Li, J, et al., & Masson, E (2017). Population pharmacokinetic and exposure simulation analysis for cediranib (AZD2171) in pooled Phase I/II studies in patients with cancer. British journal of clinical pharmacology 83(8) 1723–1733. DOI:10.1111/bcp.13266 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28213941
van Herpen, CM, et al., & de Jonge, MJ (2013). Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment. Anti-cancer drugs 24(2) 204–211. DOI:10.1097/CAD.0b013e32835bd1d2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23197081
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)